

UvA-DARE (Digital Academic Repository)

HPV in minority populations

Epidemiology and vaccination acceptability

Alberts, C.J.

Publication date 2017 Document Version Other version License Other

Link to publication

Citation for published version (APA):


Alberts, C. J. (2017). HPV in minority populations: Epidemiology and vaccination acceptability.

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.



HPV IN MINORITY POPULATIONS: epidemiology and vaccination acceptability c.j. Alberts

HPV in minority populations: epidemiology and vaccination acceptability

Catharina J. Alberts

Copyright © 2016 Catharina J. Alberts ISBN 978-90-77595-13-8

Cover: Janna Willemine Alberts

About the cover: The cover visualizes where the burden of HPV related diseases (cervical cancer) takes its highest toll, and to what degree primary prevention methods (HPV vaccination) are currently available and taken up. The color gradient on the map represents the age standardized mortality rate (from the lightest shade to the darkest shade: <2, 2.4-5.9, 5.9-9.8, 9.8-17.5, >17.5 per 100,000 women per year). The bar chart represents the HPV vaccination uptake among women (from left to right for the age group 10-14, 15-19, 20-24, 25-29 years, the tick on the vertical axis represents 50% full-course coverage).

The figures on the cover are adapted from:

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 18/09/2016.

Bruni L, Diaz M, Barrionuevo-rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Heal. 2016;4: 453–463.

Layout and printing: Optima Grafische Communicatie (www.ogc.nl)

The research presented in this thesis was financially supported by ZonMw (Programma Academische Werkplaatsen Publieke Gezondheid [50-50405-98-12]) and by internal grants from GGD Amsterdam. Financial support for the publication of this thesis was provided by Pfizer by, Condomerie, DDL Diagnostic Laboratory, Academic Medical Center, and GGD Amsterdam.

HPV IN MINORITY POPULATIONS: EPIDEMIOLOGY AND VACCINATION ACCEPTABILITY

ACADEMISCH PROEFSCHRIFT

ter verkrijging van de graad van doctor aan de Universiteit van Amsterdam op gezag van de Rector Magnificus

prof. dr. ir. K.I.J. Maex

ten overstaan van een door het College voor Promoties ingestelde commissie,

in het openbaar te verdedigen in de Aula der Universiteit

op vrijdag 3 februari 2017, te 13:00 uur

door Catharina Johanna Alberts

geboren te Voorburg

Promotiecommissie:

Promotor: Prof. dr. M. Prins Universiteit van Amsterdam

Copromotores: Dr. M.F. Schim van der Loeff GGD Amsterdam

Dr. T.G.W.M. Paulussen TNO

Overige leden: Prof. dr. S.E. Geerlings Universiteit van Amsterdam

Prof. dr. J.E.A.M. van Bergen

Prof. dr. F.G.J. Cobelens

Prof. dr. J.H. Richardus

Prof. dr. G.J. Kok

Universiteit van Amsterdam

Erasmus Universiteit Rotterdam

Universiteit van Maastricht

Dr. J. Berkhof Vrije Universiteit Amsterdam

Faculteit der Geneeskunde

TABLE OF CONTENTS

Chapter 1	Introduction	9
PART 1: EPIDI	EMIOLOGY OF HPV	
Chapter 2	Vaginal high-risk human papillomavirus infection in a cross-sectional	33
	study among women of six different ethnicities in Amsterdam, the	
	Netherlands: the HELIUS study	
Chapter 3	High-risk human papillomavirus seroprevalence in men and women of six	63
	different ethnicities in Amsterdam, the Netherlands: the HELIUS study	
Chapter 4	A cross-sectional study on the concordance between vaginal HPV DNA	97
	detection and type-specific antibodies in a multi-ethnic cohort of women	
	from Amsterdam, the Netherlands: the HELIUS study	
Chapter 5	Route of sexual exposure is independently associated with seropositivity	115
	to HPV-16 and HPV-18 among clients of an STI clinic in the Netherlands	
Chapter 6	HIV is an important risk factor for HPV-16 and HPV-18 seropositivity	131
	among sexually active men who have sex with men	
Chapter 7	Association of Chlamydia trachomatis infection and herpes simplex virus	155
	type 2 serostatus with genital human papillomavirus infection in men:	
	the HIM Study	
PART 2: HPV	VACCINATION ACCEPTABILITY	
Chapter 8	A longitudinal study on determinants of HPV vaccination uptake in	177
	parents/guardians from different ethnic backgrounds in Amsterdam, the	
	Netherlands	
Chapter 9	HPV vaccination intention among male clients of a large STI outpatient	221
	clinic in Amsterdam, the Netherlands	
Chapter 10	Discussion	251
	APPENDICES	
	Summary in English	281
	Nederlandse samenvatting	287
	Acknowledgments	295
	Biography	303
	List of publications	307
	List of contributing authors (this thesis)	315
	Portfolio	323

LIST OF ABBREVIATIONS

aOR adjusted Odds Ratio

CDC Centers for Disease Control and Prevention

CT Chlamydia trachomatis
CI Confidence interval

GEE Generalized estimating equations

GGD Geneeskundige en Gezondheidsdienst (Public Health Service)

GP General Practitioner

HELIUS Healthy Life In an Urban Setting
HIV Human Immunodeficiency Virus

HPV Human Papillomavirus

hrHPV High-risk Human Papillomavirus

HSV-2 Herpes Simplex Virus-2 IDU Injecting Drug Use

insMSM men who have sex with men (MSM) reporting to have had only insertive

(but not receptive) anal sex

IQR Interquartile Range

LSP Lifetime number of sexual partner
MFI Median Fluorescence Intensity
MSM Men who have Sex with Men
NIP National Immunization Program

OR Odds Ratio
Pap Papanicolaou

PCR Polymerase Chain Reaction

recMSM MSM reporting receptive anal sex

RIVM Rijks Instituut voor de Volksgezondheid en Milieuhygiëne (National Insti-

tute of Public Health)

SD Standard Deviation

STD Sexually Transmitted Disease
STI Sexually Transmitted Infection
WHO World Health Organization
WSM Women who have Sex with Men